Acesso livre
Acesso livre

Covid-19

Segurança das vacinas de mRNA administradas durante os primeiros 6 meses no programa de vacinação contra COVID-19 dos EUA.

9 Mar, 2022 | 13:44h

Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe – The Lancet Infectious Diseases

Comentários:

Large US study confirms most mRNA COVID-19 vaccine side effects are mild and temporary – Lancet

Covid vaccines not linked to deaths, major US study finds – BBC

Most mRNA COVID vaccine adverse events mild, transient – CIDRAP

Estudo mostra que o número de infecções por Covid-19 não identificadas por testes de fluxo lateral é “substancial o bastante para ter importância clínica.”

8 Mar, 2022 | 18:36h

Comunicado de imprensa: Number of covid-19 infections missed by lateral flow tests “substantial enough to be of clinical importance,” warn experts – BMJ

Estudo original: SARS-CoV-2 antigen lateral flow tests for detecting infectious people: linked data analysis – The BMJ

Comentários:

Lateral flow tests may be missing ‘substantial’ number of COVID-19 infections – Imperial College London

Self-testing for asymptomatic non-contacts using rapid antigen tests—is this leading to a cost effective reduction in infection transmission? – The BMJ

Dois imunologistas explicam quanto tempo dura a imunidade protetora contra COVID-19 após infecção ou vacinação.

8 Mar, 2022 | 18:34h

How long does protective immunity against COVID-19 last after infection or vaccination? Two immunologists explain – The Conversation

A próxima variante: 3 questões centrais sobre o que vem depois da Ômicron.

8 Mar, 2022 | 18:33h

The next variant: three key questions about what’s after Omicron – Nature

[Comunicado de imprensa – ainda não publicado] Nova vacina da Sanofi e GSK demonstra forte proteção contra Covid-19 grave.

8 Mar, 2022 | 18:32h

Comentário: New vaccine demonstrates strong protection against severe Covid-19 in clinical trials – CNN

Comunicado de imprensa: Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine

Revisão sistemática | Anticoagulantes para pessoas internadas com COVID-19.

8 Mar, 2022 | 17:53h

Anticoagulants for people hospitalised with COVID‐19 – Cochrane Library

Resumo: Do blood thinners prevent people who are hospitalised with COVID-19 from developing blood clots? – Cochrane Library

Conteúdo relacionado: Anticoagulation in Patients With COVID-19: JACC Review Topic of the Week.

COVID-19: como a Ômicron ultrapassou a Delta, em 3 gráficos.

8 Mar, 2022 | 17:51h

COVID-19: How Omicron overtook Delta in three charts – Nature

Artigos de revisão | Manifestações cutâneas da infecção pelo SARS-CoV-2.

8 Mar, 2022 | 17:43h

Cutaneous Manifestations of SARS-CoV-2 Infection – American Journal of Clinical Dermatology

Common skin signs of COVID-19 in adults: An update – Cleveland Clinic Journal of Medicine

[Preprint] Estudo RECOVERY mostra que baricitinibe reduz mortes em pacientes internados com COVID-19.

8 Mar, 2022 | 16:22h

Comunicado de imprensa: RECOVERY trial shows Baricitinib reduces deaths in patients hospitalised with COVID-19 – University of Oxford

Estudo original: Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis – medRxiv

Comentários:

Arthritis drug reduces mortality in severe COVID-19, huge clinical trial finds – Science

Covid-19: Anti-inflammatory treatment baricitinib reduces deaths in patients admitted to hospital, finds trial – The BMJ

Another life-saving Covid drug identified – BBC

Conteúdos relacionados:

WHO recommends two new drugs (Baricitinib and Sotrovimab) to treat COVID-19.

RCT: Baricitinib reduced mortality in hospitalized adults with COVID-19.

Randomized trial: Baricitinib plus remdesivir reduce recovery time in patients with COVID-19

 

Comentário do autor no Twitter (fio – clique para saber mais)

 

Análise sistemática | Variação na taxa de infecção-fatalidade da COVID-19 por idade, tempo e geografia durante a era pré-vacina.

8 Mar, 2022 | 16:19h

Variation in the COVID-19 infection–fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis – The Lancet

Comentário convidado: Understanding of COVID-19 from infection–fatality ratio – The Lancet

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.